| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f7ddc4774cf5f8a0bda44a780d73c53d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-605
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-575 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 |
| filingDate |
2014-01-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d02c9990cf09ee7e1451aee144a2dff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ceba070752048340ff9a5b6d9aadd3d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_690cf824ad030eb757f4f434066c3408
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_73a8d4cc16357235942e34e3fda3ffb9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aaaa024eec59427699acaa88023d52fc |
| publicationDate |
2014-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20140088837-A |
| titleOfInvention |
Insulinotropic peptide derivative wherein its N-terminal charge is modified |
| abstract |
The present invention relates to insulin secretory peptide derivatives having modified N-terminal charge and a pharmaceutical composition comprising the insulin secretory peptide derivatives. More particularly, the insulin secretory peptide derivative is characterized in that the N-terminal positive charge of the insulin secretory peptide is neutralized at a neutral pH, . The insulin secretion peptide derivative according to the present invention is characterized in that the dissociation from the GLP-1 receptor proceeds rapidly due to the modification of the N-terminal charge as described above, so that the insulin secretion peptide and the glucose And thus can be very useful for the treatment of type 2 diabetes. |
| priorityDate |
2013-01-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |